FOLLICULAR LYMPHOMA ( FL)

This is an early-stage study to find a safe dose and check the initial safety of a new CAR-T cell therapy called GF-CART01. It is for adults aged 18-70 with certain advanced B-cell blood cancers that have come back or not responded to at least two prior treatments. The therapy in…

This early-stage study is testing an experimental drug called MDX2003 for people with several types of B-cell lymphoma that have come back or stopped responding to at least two prior treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. It will…

This study is testing whether an experimental drug called odronextamab works better than the current standard treatment for people newly diagnosed with follicular lymphoma, a type of blood cancer. About 822 participants will be randomly assigned to receive either the new drug or …

This is a first-in-human study testing a new oral drug called NX-5948 in adults with advanced B-cell blood cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. The study will enroll …

This study is testing an experimental drug called surovatamig for adults whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior treatments. The main goals are to see if the drug can shrink the cancer and how safe it is for patients. Researcher…

This is the first study in people testing a new drug called LTZ-301 for adults with non-Hodgkin lymphoma that has returned or stopped responding to at least two prior treatments. The main goals are to find a safe dose and see how the body handles the drug. Researchers will also c…

This large, late-stage trial is testing whether adding a new drug, epcoritamab, to a standard treatment (rituximab and lenalidomide) works better and is safer than standard chemotherapy for adults newly diagnosed with follicular lymphoma. Follicular lymphoma is a common, slow-gro…

This study is testing whether a combination of two treatments can better control aggressive B-cell lymphomas that have returned or not responded to standard therapies. It combines a personalized cell therapy (CAR-T) that trains a patient's own immune cells to attack cancer, with …

This study is testing a new oral medicine called mevrometostat, alone and combined with an existing drug (enzalutamide), for men with advanced prostate cancer that has worsened despite prior treatment. The main goals are to find a safe dose and see if the treatment can help contr…

This study aims to discover molecular patterns in blood and tissue that might predict how patients with acute myeloid leukemia or follicular lymphoma respond to treatment. Researchers will collect samples from 550 patients during their regular care and track their health outcomes…

This study is creating a national registry to track how nearly 3,000 adults in Germany with various blood cancers are treated in real-world clinics. It aims to understand common treatment patterns, patient quality of life, and survival outcomes over time. The goal is to identify …